New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 50 mg/10 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - apixaban (unii: 3z9y7uwc1j) (apixaban - unii:3z9y7uwc1j) - apixaban 2.5 mg - eliquis is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. eliquis is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), in patients who have undergone hip or knee replacement surgery. eliquis is indicated for the treatment of dvt. eliquis is indicated for the treatment of pe. eliquis is indicated to reduce the risk of recurrent dvt and pe following initial therapy. eliquis is contraindicated in patients with the following conditions: the limited available data on eliquis use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. treatment may increase the risk of bleeding during pregnancy and delivery. in animal reproduction studies, no adverse developmental effects were seen when apixaban was administered to rats (orally), rabbits (intravenously) and mice (orally) during organogenesis at unbound apixaban exposu

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - hydrochlorothiazide; captopril - oral tablet - 25mg ; 50mg

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - powder for concentrate for solution for infusion - abatacept 250 mg - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists. polyarticular juvenile idiopathic arthritis: orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).orencia is indicated for the prophylaxis of acute graft versus host disease (agvhd), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 6 years of age or older undergoing hematopoietic stem cell transplantation (hsct) from a matched or 1 allele-mismatched unrelated-donor.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - solution for injection - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).

European Union - English - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - nivolumab 10 mg/ml;  ;  ;   - concentrate for infusion - 100 mg/10ml - active: nivolumab 10 mg/ml       excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - nivolumab 10 mg/ml;  ;  ;   - concentrate for infusion - 40 mg/4ml - active: nivolumab 10 mg/ml       excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - belatacept (unii: e3b2gi648a) (belatacept - unii:e3b2gi648a) - belatacept 250 mg - nulojix® (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. nulojix is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. use nulojix only in patients who are ebv seropositive [see contraindications (4) and warnings and precautions (5.1)] . use of nulojix for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established [see warnings and precautions (5.6)] . nulojix is contraindicated in transplant recipients who are epstein-barr virus (ebv) seronegative or with unknown ebv serostatus due to the risk of post-transplant lymphoproliferative disorder (ptld), predominantly involving the central nervous system (cns) [see boxed warning and warnings and precautions (5.1)] . to monitor maternal-fetal outcomes of pregnant women who have received immunosuppressants including nulojix or whose partners have received nulojix, healthcare providers are strongly encouraged to regis